Giant cell arteritis: Difference between revisions
No edit summary
 
(12 intermediate revisions by 7 users not shown)
Line 2: Line 2:


==Background==
==Background==
*Systemic vasculitis most commonly involving medium-sized arteries in the carotid circulation affection 1% of the population<ref>Gonzalez-Gay, MA et al. Epidemiology of the vasculitides. Rheum Dis Clin North Am. 2001;27:729-749</ref>
[[File:Histopathology of giant cell arteritis.png|thumb|Giant cell arteritis on histopathology.]]
[[File:Gray508.png|thumb|The arteries of the face and scalp.]]
*Systemic [[vasculitis]] most commonly involving medium-sized arteries in the carotid circulation, affecting 1% of the population<ref>Gonzalez-Gay, MA et al. Epidemiology of the vasculitides. Rheum Dis Clin North Am. 2001;27:729-749</ref>
**Temporal artery is the most commonly involved, but ophthalmic, occipital, and other arteries off the aorta can also be involved
**Most frequent primary large-vessel vasculitis in patients over 50<ref>Régent A, Mouthon L. Treatment of Giant Cell Arteritis (GCA). J Clin Med. 2022 Mar 24;11(7):1799. doi: 10.3390/jcm11071799. PMID: 35407411; PMCID: PMC8999932.</ref>
**Elevated risk in women and Northern European descent
*Giant cell arteritis, with possible involvement of large vessels like aorta leading to<ref>Morabito GC, Tartaglino B. Chapter 279. Emergencies in Systemic Rheumatic Diseases. In:  JE, Stapczynski JS, Cline DM, Ma OJ, Cydulka RK, Meckler GD, eds. 's Emergency Medicine: A Comprehensive Study Guide. 7th ed. New York: McGraw-Hil</ref>:
*Giant cell arteritis, with possible involvement of large vessels like aorta leading to<ref>Morabito GC, Tartaglino B. Chapter 279. Emergencies in Systemic Rheumatic Diseases. In:  JE, Stapczynski JS, Cline DM, Ma OJ, Cydulka RK, Meckler GD, eds. 's Emergency Medicine: A Comprehensive Study Guide. 7th ed. New York: McGraw-Hil</ref>:
**[[Temporal arteritis]]
**[[Temporal arteritis]]
Line 8: Line 13:
**Aortic arch syndrome
**Aortic arch syndrome
**[[Aortic dissection]]
**[[Aortic dissection]]
*Elevated risk in Women and 50-70 yrs of age
*"Rule of 50s" can help remember useful points - "temporal arteritis affects patients at least 50 years of age, with a serum ESR > 50 mm/hr and is treated with 50mg of [[prednisone]] daily"
*"Rule of 50s" can help remember useful points - "temporal arteritis affects patients at least 50 years of age, with a serum ESR > 50 mm/hr and is treated with 50mg of [[prednisone]] daily"
*Can cause painless, ischemic optic neuropathy with severe vision loss if left untreated
*Can cause painless, ischemic optic neuropathy with severe vision loss if left untreated
*Associated with [[polymyalgia rheumatica]] <ref> Lehrmann JF, Sercombe CT: Systemic Lupus Erythmatosus and the Vasculitides, in Marx JA, Hockberger RS, Walls RM, et al (eds): Rosen’s Emergency Medicine: Concepts and Clinical Practice, ed 7. St. Louis, Mosby, Inc., 2010, (Ch) 116: p 1497-1510.</ref>
*Associated with [[polymyalgia rheumatica]] <ref> Lehrmann JF, Sercombe CT: Systemic Lupus Erythmatosus and the Vasculitides, in Marx JA, Hockberger RS, Walls RM, et al (eds): Rosen’s Emergency Medicine: Concepts and Clinical Practice, ed 7. St. Louis, Mosby, Inc., 2010, (Ch) 116: p 1497-1510.</ref>
**50% of patients with Giant Cell Arteritis have concomitant Polymylalgia Rheumatica. 15% of patients with Polymyalgia Rheumatica develop Giant Cell Arteritis
**50% of patients with Giant Cell Arteritis have concomitant Polymylalgia Rheumatica. 15% of patients with Polymyalgia Rheumatica develop Giant Cell Arteritis
{{Primary Vasculitis DDX}}


==Clinical Features==
==Clinical Features==
*[[Fever]]
*[[Fever]] or other constitutional symptoms
*[[Headache]] in 85%
*[[Headache]] in 85%
**Gradually worsens over days
**Gradually worsens over days, worse at night
**Worse at night
**Usually unilateral near temple/periorbital area, but can be nonfocal
**Usually unilateral near temple
**May have tender scalp on palpation
*Tender pulseless temporal artery
*Jaw claudication
*Jaw claudication
**Weight Loss
*[[Myalgia]] ([[polymyalgia rheumatica]])
*Myalgias (polymyalgia rheumatica)
*[[Visual loss]] in one eye in 50%
*Visual loss in one eye in 50%
**Posterior ciliary artery
**Posterior ciliary artery
**May present as amaurosis fugax
**May present as amaurosis fugax, transient diplopia, or complete blindness
**Second eye may be affected within weeks after first
**Second eye may be affected within weeks after first
===American College of Rheumatology Criteria<ref>Hunder GG. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.  Arthritis Rheum.  1990; 33(8):1122-8 </ref>===
*Tender, pulseless temporal artery
*3 or more criteria 93% sensitive and 91% specific
*Afferent pupillary defect
**Age ≥ 50 years old
*Pale and edematous optic disc
**New onset of headache
**Temporal artery tenderness or DECREASED temporal pulse (not related to carotid disease)
**ESR ≥ 50 mm/hr
**Artery biopsy with necrotizing arteritis or a granulomatous process with multinucleated giant cells


===Likelihood Ratio of Findings===
===Likelihood Ratio of Findings===
Line 60: Line 60:
==Differential Diagnosis==
==Differential Diagnosis==
{{Headache DDX}}
{{Headache DDX}}
{{Acute vision loss noninflamed DDX}}
{{Acute vision loss noninflamed DDX}}
{{Primary Vasculitis DDX}}


==Evaluation==
==Evaluation==
*Temporal artery tenderness
*Afferent pupillary defect
*Pale and edematous optic disc
*ESR ~70-110
*ESR ~70-110
**84% sensitivity, 30% specificity<ref>Kermani TA, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012; 41:866–871.</ref>
**84% sensitivity, 30% specificity<ref>Kermani TA, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012; 41:866–871.</ref>
**>15% of patients can have a normal ESR
**>15% of patients can have a normal ESR
*CRP elevated, may be more sensitive than ESR and doesn't have normal age related increase like ESR does<ref>Kermani et al. Utility of Erythrocyte Sedimentation Rate and C-Reactive Protein for the Diagnosis of Giant Cell Arteritis. Semin Arthritis Rheum. 2012 Jun; 41(6): 866–871.</ref>
*CRP elevated<ref>Kermani et al. Utility of Erythrocyte Sedimentation Rate and C-Reactive Protein for the Diagnosis of Giant Cell Arteritis. Semin Arthritis Rheum. 2012 Jun; 41(6): 866–871.</ref>
*4% of patients have normal CRP and ESR with biopsy confirmed diagnosis<ref>Jhun P, et al. Giant Cell Arteritis: Read the Fine Print!  Ann Em Med. 2015; 65(5):615–617.</ref>
**More sensitive than ESR
**Doesn't have normal age related increase like ESR does
*The role of ESR/CRP is more to rule out (if both normal) rather than to confirm the diagnosis when they are elevated. 4% of patients have normal CRP and ESR with biopsy confirmed diagnosis<ref>Jhun P, et al. Giant Cell Arteritis: Read the Fine Print!  Ann Em Med. 2015; 65(5):615–617.</ref>
 
*Ultrasound<ref>Hernández P, Al Jalbout N, Matza M, Kohler MJ, Shokoohi H. Temporal Artery Ultrasound for the Diagnosis of Giant Cell Arteritis in the Emergency Department. Cureus. 2023 Jul 24;15(7):e42350. doi: 10.7759/cureus.42350. PMID: 37621789; PMCID: PMC10445179.</ref>
**Increasingly used as a first-line investigation due to availability/speed and ability to capture larger segments of the artery
**May show a noncompressible involved artery with hypoechoic wall thickening<ref>Wolfgang A Schmidt, Ultrasound in the diagnosis and management of giant cell arteritis, Rheumatology, Volume 57, Issue suppl_2, February 2018, Pages ii22–ii31, https://doi.org/10.1093/rheumatology/kex461</ref>
 
===American College of Rheumatology Criteria<ref>Hunder GG. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.  Arthritis Rheum.  1990; 33(8):1122-8 </ref>===
*3 or more criteria 93% sensitive and 91% specific
**Age ≥ 50 years old
**New onset of headache
**Temporal artery tenderness or DECREASED temporal pulse (not related to carotid disease)
**ESR ≥ 50 mm/hr
**Artery biopsy with necrotizing arteritis or a granulomatous process with multinucleated giant cells


==Management==
==Management==
*[[Methylprednisolone]] 1000mg IV QD x3d
*[[Methylprednisolone]] 500-1000mg IV QD x3d as a pulse dose <ref>Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-1365. doi: 10.1002/art.41774. Epub 2021 Jul 8. PMID: 34235884.</ref>
*Needs temporal artery biopsy
**Alternatively, [[Prednisone]] 1 mg/kg/day up to 80 mg as starting dose
**Expeditious steroid therapy prevents stroke of the involved artery or permanent vision loss
*Needs temporal artery biopsy, although treatment with high dose corticosteroids should be initiated prior to biopsy to avoid permanent vision loss as a result of ophthalmic artery involvement.
**Biopsy should be done as soon as possible, but may be positive as long as 2 weeks after steroid initiation<ref>Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994 Jun 15;120(12):987-92. doi: 10.7326/0003-4819-120-12-199406150-00003. PMID: 8185147.</ref>


==Disposition==
==Disposition==
Line 87: Line 98:
==References==
==References==
<references/>
<references/>
==Videos==
{{#widget:YouTube|id=6nKZ1X-ZYGI}}


[[Category:Ophthalmology]]
[[Category:Ophthalmology]]
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Rheumatology]]
[[Category:Rheumatology]]

Latest revision as of 14:50, 11 October 2023

The term "temporal arteritis" is no longer used. It refers to giant cell arteritis that affects the temporal artery.

Background

Giant cell arteritis on histopathology.
The arteries of the face and scalp.
  • Systemic vasculitis most commonly involving medium-sized arteries in the carotid circulation, affecting 1% of the population[1]
    • Temporal artery is the most commonly involved, but ophthalmic, occipital, and other arteries off the aorta can also be involved
    • Most frequent primary large-vessel vasculitis in patients over 50[2]
    • Elevated risk in women and Northern European descent
  • Giant cell arteritis, with possible involvement of large vessels like aorta leading to[3]:
  • "Rule of 50s" can help remember useful points - "temporal arteritis affects patients at least 50 years of age, with a serum ESR > 50 mm/hr and is treated with 50mg of prednisone daily"
  • Can cause painless, ischemic optic neuropathy with severe vision loss if left untreated
  • Associated with polymyalgia rheumatica [4]
    • 50% of patients with Giant Cell Arteritis have concomitant Polymylalgia Rheumatica. 15% of patients with Polymyalgia Rheumatica develop Giant Cell Arteritis

Vasculitis Syndrome Types

Clinical Features

  • Fever or other constitutional symptoms
  • Headache in 85%
    • Gradually worsens over days, worse at night
    • Usually unilateral near temple/periorbital area, but can be nonfocal
    • May have tender scalp on palpation
  • Jaw claudication
  • Myalgia (polymyalgia rheumatica)
  • Visual loss in one eye in 50%
    • Posterior ciliary artery
    • May present as amaurosis fugax, transient diplopia, or complete blindness
    • Second eye may be affected within weeks after first
  • Tender, pulseless temporal artery
  • Afferent pupillary defect
  • Pale and edematous optic disc

Likelihood Ratio of Findings

Jaw claudication and a beaded temporal artery increase the likelihood of temporal arteritis the greatest[5]

Finding (+) Likelihood Ratio of Temporal Ateritis Negative Likelihood Ratio
Jaw claudication 4.2 (2.8-6.2) 0.72 (0.65 - 0.81)
Diplopia 3.4 (1.3-8.6) 0.95 (0.91 - 0.99)
Temporal artery beading 4.6 (1.1 - 18.4) 0.93 (0.88-0.99)
Enlarged temporal artery 4.3 (2.1-8.9) 0.67 (0.5-0.89)
Painful temporal artery 2.6 (1.9-3.7) 0.82 (0.74-0.92)
Absent temporal artery pulse 2.7 (0.55 - 13.4) 0.71 (0.38 - 1.3)
Abnormal ESR 1.1 (1.0-1.2) 0.2 (0.08 - 0.51)

Differential Diagnosis

Headache

Common

Killers

Maimers

Others

Aseptic Meningitis

Acute Vision Loss (Noninflamed)

†Emergent Diagnosis

Evaluation

  • ESR ~70-110
    • 84% sensitivity, 30% specificity[6]
    • >15% of patients can have a normal ESR
  • CRP elevated[7]
    • More sensitive than ESR
    • Doesn't have normal age related increase like ESR does
  • The role of ESR/CRP is more to rule out (if both normal) rather than to confirm the diagnosis when they are elevated. 4% of patients have normal CRP and ESR with biopsy confirmed diagnosis[8]
  • Ultrasound[9]
    • Increasingly used as a first-line investigation due to availability/speed and ability to capture larger segments of the artery
    • May show a noncompressible involved artery with hypoechoic wall thickening[10]

American College of Rheumatology Criteria[11]

  • 3 or more criteria 93% sensitive and 91% specific
    • Age ≥ 50 years old
    • New onset of headache
    • Temporal artery tenderness or DECREASED temporal pulse (not related to carotid disease)
    • ESR ≥ 50 mm/hr
    • Artery biopsy with necrotizing arteritis or a granulomatous process with multinucleated giant cells

Management

  • Methylprednisolone 500-1000mg IV QD x3d as a pulse dose [12]
    • Alternatively, Prednisone 1 mg/kg/day up to 80 mg as starting dose
    • Expeditious steroid therapy prevents stroke of the involved artery or permanent vision loss
  • Needs temporal artery biopsy, although treatment with high dose corticosteroids should be initiated prior to biopsy to avoid permanent vision loss as a result of ophthalmic artery involvement.
    • Biopsy should be done as soon as possible, but may be positive as long as 2 weeks after steroid initiation[13]

Disposition

  • Admission

See Also

References

  1. ↑ Gonzalez-Gay, MA et al. Epidemiology of the vasculitides. Rheum Dis Clin North Am. 2001;27:729-749
  2. ↑ Régent A, Mouthon L. Treatment of Giant Cell Arteritis (GCA). J Clin Med. 2022 Mar 24;11(7):1799. doi: 10.3390/jcm11071799. PMID: 35407411; PMCID: PMC8999932.
  3. ↑ Morabito GC, Tartaglino B. Chapter 279. Emergencies in Systemic Rheumatic Diseases. In: JE, Stapczynski JS, Cline DM, Ma OJ, Cydulka RK, Meckler GD, eds. 's Emergency Medicine: A Comprehensive Study Guide. 7th ed. New York: McGraw-Hil
  4. ↑ Lehrmann JF, Sercombe CT: Systemic Lupus Erythmatosus and the Vasculitides, in Marx JA, Hockberger RS, Walls RM, et al (eds): Rosen’s Emergency Medicine: Concepts and Clinical Practice, ed 7. St. Louis, Mosby, Inc., 2010, (Ch) 116: p 1497-1510.
  5. ↑ Smetana GW, et al. Does this patient have temporal arteritis? JAMA. 2002;287:92-101
  6. ↑ Kermani TA, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012; 41:866–871.
  7. ↑ Kermani et al. Utility of Erythrocyte Sedimentation Rate and C-Reactive Protein for the Diagnosis of Giant Cell Arteritis. Semin Arthritis Rheum. 2012 Jun; 41(6): 866–871.
  8. ↑ Jhun P, et al. Giant Cell Arteritis: Read the Fine Print! Ann Em Med. 2015; 65(5):615–617.
  9. ↑ Hernández P, Al Jalbout N, Matza M, Kohler MJ, Shokoohi H. Temporal Artery Ultrasound for the Diagnosis of Giant Cell Arteritis in the Emergency Department. Cureus. 2023 Jul 24;15(7):e42350. doi: 10.7759/cureus.42350. PMID: 37621789; PMCID: PMC10445179.
  10. ↑ Wolfgang A Schmidt, Ultrasound in the diagnosis and management of giant cell arteritis, Rheumatology, Volume 57, Issue suppl_2, February 2018, Pages ii22–ii31, https://doi.org/10.1093/rheumatology/kex461
  11. ↑ Hunder GG. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990; 33(8):1122-8
  12. ↑ Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-1365. doi: 10.1002/art.41774. Epub 2021 Jul 8. PMID: 34235884.
  13. ↑ Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994 Jun 15;120(12):987-92. doi: 10.7326/0003-4819-120-12-199406150-00003. PMID: 8185147.

Videos

{{#widget:YouTube|id=6nKZ1X-ZYGI}}

Retrieved from "https://www.wikem.org/w/index.php?title=Giant_cell_arteritis&oldid=371670"